Informações de Novartis AG

Mais detalhes de Novartis AG Empresa

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.



Código da empresaNVS

Nome da EmpresaNovartis AG

Data de listagemMay 07, 2001

CEODr. Vasant (Vas) Narasimhan, M.D.

Número de funcionários75883

Tipo de títulosOrdinary Share

Fim do ano fiscalMay 07

EndereçoLichtstrasse 35

CidadeBASEL

Bolsa de valoresJohannesburg Stock Exchange

PaísSwitzerland

Código postal4056

Telefone41613241111

Sitehttps://www.novartis.com/

Código da empresaNVS

Data de listagemMay 07, 2001

CEODr. Vasant (Vas) Narasimhan, M.D.

Executivos da empresa Novartis AG



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Robert (Rob) Kowalski

Chief People and Organization Officer, Member of the Executive Committee

--

Mr. Giovanni Caforio, M.D.

Chairman of the Board

--

Ms. Elizabeth (Liz) Doherty

Non-Executive Independent Director

--

Mr. Ton Buechner

Non-Executive Independent Director

--

Mr. Aaron (Ronny) Gal, Ph.D.

Chief Strategy and Growth Officer, Member of the Executive Committee

--

Mr. Victor Bulto

President - US, Member of the Executive Committee

--

Ms. Charlotte Pamer- Wieser, Ph.D.

Corporate Secretary

--

Ms. Karen L. Hale

Chief Legal & Compliance Officer, Member of the Executive Committee

--

Mr. Frans van Houten

Non-Executive Independent Director

--

Ms. Elizabeth Mcnally

Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Robert (Rob) Kowalski

Chief People and Organization Officer, Member of the Executive Committee

--

Mr. Giovanni Caforio, M.D.

Chairman of the Board

--

Ms. Elizabeth (Liz) Doherty

Non-Executive Independent Director

--

Mr. Ton Buechner

Non-Executive Independent Director

--

Mr. Aaron (Ronny) Gal, Ph.D.

Chief Strategy and Growth Officer, Member of the Executive Committee

--

Mr. Victor Bulto

President - US, Member of the Executive Committee

--

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Rest of portfolio

2.47B

17.58%

Cardiovascular, Renal and Metabolism - Entresto

2.36B

16.77%

Immunology - Cosentyx

1.63B

11.59%

Oncology -Kisqali

1.18B

8.37%

Neuroscience - Kesimpta

1.08B

7.66%

Outro

5.34B

38.02%

Por RegiãoUSD

Nome

Receita

Proporção

US

6.25B

44.46%

Europe

4.17B

29.67%

Asia / Africa / Australasia

2.71B

19.30%

Canada and Latin America

922.00M

6.56%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Rest of portfolio

2.47B

17.58%

Cardiovascular, Renal and Metabolism - Entresto

2.36B

16.77%

Immunology - Cosentyx

1.63B

11.59%

Oncology -Kisqali

1.18B

8.37%

Neuroscience - Kesimpta

1.08B

7.66%

Outro

5.34B

38.02%

Distribuição de ações

Atualizado em: sex, 15 de ago

Investidores

Tipos de investidores

Investidores

Proporção

Dodge & Cox

0.55%

PRIMECAP Management Company

0.54%

Dimensional Fund Advisors, L.P.

0.47%

Fisher Investments

0.37%

Loomis, Sayles & Company, L.P.

0.29%

Outro

97.77%

Investidores

Proporção

Dodge & Cox

0.55%

PRIMECAP Management Company

0.54%

Dimensional Fund Advisors, L.P.

0.47%

Fisher Investments

0.37%

Loomis, Sayles & Company, L.P.

0.29%

Outro

97.77%

Tipos de investidores

Investidores

Proporção

Investment Advisor

3.26%

Investment Advisor/Hedge Fund

2.94%

Research Firm

0.38%

Hedge Fund

0.31%

Bank and Trust

0.13%

Pension Fund

0.03%

Family Office

0.02%

Outro

92.94%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

1967

135.58M

7.06%

-11.39M

2025Q2

1941

140.71M

7.27%

+2.13M

2025Q1

1953

141.07M

7.20%

+870.45K

2024Q4

1926

134.00M

6.78%

-9.24M

2024Q3

1858

134.89M

6.74%

-11.71M

2024Q2

1840

139.20M

6.87%

-9.16M

2024Q1

1808

141.30M

6.92%

-7.93M

2023Q4

1811

141.99M

6.94%

-15.97M

2023Q3

1775

150.92M

7.33%

-7.18M

2023Q2

1759

150.74M

7.28%

-24.15M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Dodge & Cox

10.65M

0.55%

-1.17M

-9.90%

Jun 30, 2025

PRIMECAP Management Company

10.40M

0.54%

+18.55K

+0.18%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

9.06M

0.47%

+454.17K

+5.28%

Jun 30, 2025

Fisher Investments

7.12M

0.37%

+358.28K

+5.30%

Jun 30, 2025

Loomis, Sayles & Company, L.P.

5.58M

0.29%

+78.48K

+1.43%

Jun 30, 2025

Franklin Mutual Advisers, LLC

4.16M

0.21%

-702.88K

-14.45%

Jun 30, 2025

Morgan Stanley Smith Barney LLC

3.65M

0.19%

+129.18K

+3.67%

Jun 30, 2025

Parametric Portfolio Associates LLC

3.08M

0.16%

+80.38K

+2.68%

Jun 30, 2025

Managed Account Advisors LLC

2.92M

0.15%

+7.18K

+0.25%

Jun 30, 2025

Wellington Management Company, LLP

2.50M

0.13%

-488.93K

-16.34%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

VanEck Pharmaceutical ETF

9.73%

Amplify International Enhanced Dividend Income ETF

3.98%

Abacus FCF International Leaders ETF

3.53%

Altrius Global Dividend ETF

2.34%

Invesco International Dividend Achievers ETF

2.14%

Freedom Day Dividend ETF

2.11%

DFA Dimensional Internatl High Profitability ETF

1.68%

Fundamentals First ETF

1.58%

SP Funds S&P World (ex-US) ETF

1.55%

Brandes International ETF

1.27%

Ver Mais

VanEck Pharmaceutical ETF

Proporção9.73%

Amplify International Enhanced Dividend Income ETF

Proporção3.98%

Abacus FCF International Leaders ETF

Proporção3.53%

Altrius Global Dividend ETF

Proporção2.34%

Invesco International Dividend Achievers ETF

Proporção2.14%

Freedom Day Dividend ETF

Proporção2.11%

DFA Dimensional Internatl High Profitability ETF

Proporção1.68%

Fundamentals First ETF

Proporção1.58%

SP Funds S&P World (ex-US) ETF

Proporção1.55%

Brandes International ETF

Proporção1.27%

Dividendo



Um total de 36.74B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Feb 20, 2025

NVS.NB Approximate final Cash Dividend of gross USD 3.869541 going ex on Mar 12, 2025

Mar 12, 2025

May 01, 2025

Mar 12, 2025

Feb 12, 2024

NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024

Mar 08, 2024

Apr 19, 2024

Mar 07, 2024

Feb 02, 2023

NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023

Mar 10, 2023

Mar 20, 2023

Mar 09, 2023

Feb 04, 2022

NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022

Mar 09, 2022

Mar 17, 2022

Mar 08, 2022

Jan 26, 2021

NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021

Mar 05, 2021

Mar 15, 2021

Mar 04, 2021

Jan 31, 2020

NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020

Mar 04, 2020

Mar 12, 2020

Mar 03, 2020

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados